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108 Poster Session IIresp. 23 pts (16.8%) died from transplant related mortality
(TRM)(d1 100). 20 pts (14.6%) had relapse at 132 days from trans-
plant (6–1097). 53.3% pts developed acute GVHD, 17.5% chronic
GVHD. 75 pts (54.7%) are event free survivors (EFS) with median
f/u of 3234 days. Overall Survival (OS) is 52.9% with f/u of 896
days. UCB: 67.6% achieved ANC, 62.1% achieved PLT at median
of 26 days (14–62) and 46 days (14–105) resp. 26 pts (21.8%) died
from TRM. 19 pts (16%) had relapse in 53 days (21–503). 54.6%
had acute GVHD, 9.2% had chronic GVHD. 65 (54.6%) are
EFS at present with f/u of 1967 days and OS is 52.2% with f/u of
769 days. Conclusion: Patients undergoing a single allogeneic
transplant with BM or UCB, show no statistical difference in
TRM, Relapse, EFS, OS or acute GVHD. A statistically significant
difference was found in age, infused cells dose, time to engraftment
and in chronic GVHD. UCB patients were younger, received lower
cell dose and have less chronic GVHD.Transplant Characteristics & Outcomes
BM UCB p valuePatient
Age (years) 9.2 ± 0.4 5.4 ± 0.4 \0.0001Cell Dose
dose CD34  106/kg 1.5 ± 0.1 0.7 ± 0.05 \0.0001
TNC  108/kg 2.7 ± 0.1 0.8 ± 0.06 \0.0001Outcome Measures
ANC .500 cells/mL
(days)18.3 ± 0.8 22.3 ± 0.8 0.0014PLT .20,000 cells/mL
(days)32.9 ± 3.3 46.5 ± 2.4 0.0026TRM % 16.8 21.8 not significant
Relapse % 14.6 16 not significant
EFS % 54.7 54.6 not significant
OS % 52.9 52.2 not significant
Acute GVHD % 53.3 54.6 not significant
Chronic GVHD % 17.5 9.2 0.03292
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We investigated in a canine model whether combining three
postgrafting immunosuppressive drugs averted late graft rejection
after conditioning with 1 Gy of TBI, which was consistently seen
in historical dogs given two drugs. Sixteen dogs were given four dif-
ferent three-drug combinations after 1Gy TBI and DLA-identical
marrow grafts (Table). All 16 dogs showed initial engraftment.
Thirteen dogs rejected their grafts after a median duration of donor
chimerism of 9 weeks, while 3 dogs had sustained grafts for .26
weeks. The 3 dogs with durable mixed chimerism had received a me-
dian number of 6.14  108 nucleated marrow cells/kg compared to
3.6 108/kg given to the 13 dogs with rejection (p5 0.03). To con-
firm this finding, we constructed Cox regression model including
the 16 current dogs and 16 historical dogs receiving 1 Gy TBI
and given dual immunosuppression. After adjusting for immuno-
suppressive regimens received, each increase of 1 108/kg of nucle-
ated marrow cell doses decreased the hazard of rejection by 0.5 (p5
0.003). We also assessed the effects of TBI doses of 2.0 and 1.0 Gy
on immune functions in 2 dogs each which were not given marrow
grafts. The mean nadirs among dogs given 2 Gy versus 1 Gy TBI
were 376 versus 753 cells/ml, respectively. Statistically significant re-
ductions in CD3 and CD4 nadirs (p\ 0.001 for all), but not CD8
nadirs (p5 0.38), at day 14 were observed in dogs given 2Gy versus
1 Gy TBI. Moreover, the lymph node contents of CD3, CD4, and
CD8 cells were significantly lower in dogs given 2 Gy TBI com-
pared to 1 Gy TBI (p\ 0.001 for all). One functional assay used,
lymphocyte proliferation in response to DLA-mismatched stimula-tor cells, failed to show clear differences between dogs given either 2
Gy or 1 Gy TBI. An in-vivo functional assay, B-cell and T-cell de-
pendent production of IgM and IgG antibodies in response to sheep
red blood cell injections, showed a trend and statistically significant
greater suppressions of IgM and IgG antibody formation (p 5 0.08
and 0.008, respectively) after 2 Gy compared to 1 Gy TBI. Overall,
triple postgrafting immunosuppression after 1 Gy TBI was well tol-
erated but failed to prevent graft rejection in this model. In-vivo ra-
diation studies have shown higher numbers of remaining host
lymphocytes and better T-cell dependent antibody production after
1Gy compared to 2 Gy TBI. Transplanting larger number of donor
marrow cells might improve the rate of engraftment after 1 Gy TBI
Table. Marrow grafts from DLA-identical littermates/siblings after
conditioning with 1 Gy TBI followed by 4 different combinations of triple
postgrafting immunosuppression
Maximum donor DurationTriple
immunosuppressive
combinations
DNucleated
marrow
cells
( 106/kg)
Gchimerism of mixed
hematopoietic
chimerism
(weeks after
marrow graft) rog
No.ranulocytes
%
PBMC
%Graft
ejection
Autologous
recoveryGroup 1MMF, 10 mg/kg
bid SC on days
0 to 27
G199 3.8 5 5 Yes 9 Yes1 CSP, 10 mg/kg
bid orally on
days - 1 to 35
G217 3.6 56 17 Yes 12 Yes1 SRL, 0.05
mg/kg once
daily SC on
days 0 to 27
G246 4.04 3 55 Yes 9 YesG284 3.6 20 14 Yes 20 YesG286 5.1 15 10 Yes 12 YesGroup 2MMF, 10 mg/kg
bid SC on
days 0 to 27
G234 5.71 50 40 Yes 9 Yes1 CSP, 15 mg/kg
bid orally on
days - 1 to 35
G274 2.5 25 15 Yes 7 Yes1 MTX, 0.4
mg/kg IV on
days 1, 3, 6, and 11
G244 7.98 65 50 No .26 NoG283 2.78 14 10 Yes 9 YesG225 3.63 50 35 Yes 11 YesGroup 3MTX, 0.4 mg/kg
IV on days 1, 3,
6, and 11
G367 5.43 10 8 Yes 9 Yes1 CSP, 10 mg/kg
bid orally on
days - 1 to 35
G432 3 71 57 Yes 11 Yes1 SRL, 0.05
mg/kg once
daily SC on
days 0 to 27
G424 5.75 38 31 No .26 NoGroup 4MMF, 10 mg/kg
bid SC on days
0 to 41 followed
by a 20% taper
per week
until day 69
G359 1.76 15 13 Yes 9 Yes1 CSP, 10 mg/kg
bid orally on
days - 1 to 27
G391 1.47 15 14 Yes 14 Yes1 SRL, 0.05
mg/kg once daily
SC on days 0 to
41 followed by a
20% taper per
week until day 69
G247 4.7 55 30 No .26 NoCSP indicates cyclosporine; MMF, mycophenolate mofetil; SRL, si-
rolimus; MTX, methotrexate; PBMC, peripheral blood mononu-
clear cells; BID, twice daily; PO, orally; and SC, subcutaneously.
